Coherus terminates 51 jobs post FDA rejection

By Flora Southey contact

- Last updated on GMT

iStock/Devonyu
iStock/Devonyu

Related tags: Etanercept, U.s. securities and exchange commission

Coherus Biosciences has submitted a US Securities and Exchange Commission filing, announcing it will eliminate 51 jobs to reduce operating costs.

The company said the decision to restructure follows on from the US Food and Drug Administration’s (FDA) complete response letter (CRL) regarding a licensing application for the biosimilar version of Amgen’s cancer drug Neulasta (pegfilgrastim).  

The Biosimilar License Application (BLA) for CHS-1701, or pegfilgrastim, was rejected​ in its present form on June 12.

In the letter, the FDA said Coherus needs to reanalyse certain patient data. The agency also asked the firm to provide additional manufacturing information.  

In a statement​ released on the same day, Coherus said it planned to work with the FDA to address the information requests.

The firm has been gearing three late-stage clinical products towards commercialisation: CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar).

Coherus did not respond to our request for comment.

Pegfilgrastim delays

Coherus initially planned​ to file CHS-1701 in the second quarter of 2016, however on December 8, 2015 the firm announced it would delay filing in order to conduct further tests on volunteers.

When reporting the delay, CEO Danny Lanfear said, “The recent pharmacokinetic/pharmacodynamics (PK/PD) study is acceptable to support filing the BLA. However, given the low cost and relatively short delay involved, it is most prudent to initiate a follow-on study in healthy volunteers.”

“We believe this will remove any residual uncertainty, reduce regulatory risk and potential for BSUFA ​[biosimilar user fee act] timeline delays, and ultimately increase the likelihood of first cycle approval of CHS-1701,” ​he said.

Coherus is not the only developer to have a pegfilgrastim biosimilar rejected in the US.

Last year​ the FDA rejected Sandoz’s biosimilar version of Amgen’s Neulasta.

Sandoz’s parent company Novartis said at the time, “Sandoz received a complete response letter from the FDA for biosimilar pegfilgrastim candidate Neulasta. We are working with the agency to address remaining questions.”

Sandoz’s pegfilgrastim candidate is yet to be approved by the FDA.

Related topics: Markets & Regulations

Related news

Show more

Follow us

Products

View more

Webinars